Clinical Trials Sponsored by Biomendi S.A.U.

Total 224 results

University of Alicante
Pharmactive Biotech Products S.L.U

Completed

Effects of CROCUVIS+® on Computer Vision Syndrome, Sleep and Mood Disorders

Mood Disorders | Sleep Disorder | Computer Vision Syndrome

Spain
Salud Mental Integral S.A.S.
Universidad de Antioquia

Completed

Brief Group Psychoeducation for Schizophrenia

Schizophrenia
Universitat de Lleida
Pharmactive Biotech Products S.L.U

Recruiting

ABG+/GarlACE Effects on Cardiovascular Risk Factors in Subjects With Grade I Hypertension (GARDOSE)

Hypertension

Spain
Hipra Scientific, S.L.U
Veristat, Inc.; Asphalion; VHIR

Recruiting

Open-label, Multi-centre, Non-Inferiority Study of Safety and Immunogenicity of BIMERVAX for the Prevention of COVID-19 in Adolescents From 12 Years to Less Than 18 Years of Age.

SARS CoV 2 Infection

Spain
Jena University Hospital
KKS Netzwerk; iVascular S.L.U.

Completed

Effectiveness of Paclitaxel-coated Luminor® Balloon Catheter Versus Uncoated Balloon Catheter in the Arteria Femoralis Superficialis (EffPac)

Peripheral Arterial Disease

Germany
Harbour BioMed US, Inc.

Not yet recruiting

A Study Evaluating the Safety, Tolerance and Anti-tumor Activity of HBM1020 in Subjects With Advanced Solid Tumors

Advanced Solid Tumor
UnicoCell Biomed CO. LTD

Recruiting

Efficacy and Safety of ELIXCYTE Intra-articular Injection in Subject With Knee Osteoarthritis

Knee Osteoarthritis

Taiwan
BioMed Valley Discoveries, Inc

Recruiting

Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies

Gastrointestinal Cancer | Tumor, Solid

United States
BioMed Valley Discoveries, Inc

Terminated

Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations

Advanced Solid Tumor | MAP2K1 Gene Mutation | BRAF Gene Mutation | MEK Mutation | BRAF Gene Alteration | MEK Alteration | MAP2K1 Gene Alteration | MAP2K2 Gene Mutation | MAP2K2 Gene Alteration

United States
BioMed Valley Discoveries, Inc

Completed

Safety Study of Intratumoral Injection of Clostridium Novyi-NT Spores to Treat Patients With Solid Tumors That Have Not Responded to Standard Therapies

Solid Tumor Malignancies

United States
BioMed Valley Discoveries, Inc

Completed

Absorption, Metabolism and Excretion (AME) of Single Dose Radiolabeled BVD-523 in Volunteers

Healthy
BioMed Valley Discoveries, Inc

Terminated

[124I]FIAU PET-CT Scanning in Patients With Pain in a Prosthetic Knee or Hip Joint (PJI)

Prosthetic Joint Infections

United States
BioMed Valley Discoveries, Inc

Terminated

Safety Study of Clostridium Novyi-NT Spores to Treat Patients With Solid Tumors That Have Not Responded to Standard Therapies

Solid Tumor Malignancies

United States
BioMed Valley Discoveries, Inc

Completed

Biodistribution and Dosimetry Evaluation of [124I]FIAU

Prosthesis Related Infections

United States
Biomed Research & Technologies, Inc.

Completed

A Study of BRT-FC-83C for the Treatment of Atopic Dermatitis

Atopic Dermatitis

United States
Orchestra BioMed, Inc
Medtronic

Recruiting

BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT (BACKBEAT)

Hypertension | Hypertension, Systolic | Hypertension,Essential

United States, Czechia, Spain, Hungary, Belgium
Harbour BioMed US, Inc.

Completed

A Study Evaluating the Safety, Tolerance and Anti-tumor Activity of a Study Drug in Subjects With Advanced Solid Tumors

Advanced Solid Tumor

Australia, China, Hong Kong
BioMed Valley Discoveries, Inc

Completed

Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies

Advanced Solid Tumors

United States
BioMed Valley Discoveries, Inc

Completed

Phase 1/2 Study of the ERK1/2 Inhibitor BVD-523 in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndromes

Myelodysplastic Syndrome | Acute Myelogenous Leukemia

United States
BioMed Valley Discoveries, Inc

Terminated

[124I]FIAU PET-CT Scanning in Diagnosing Osteomyelitis in Patients With Diabetic Foot Infection

Diabetic Foot Infection

United States
KC BioMediX, Inc
Innara Health, Inc.

Unknown

Trial of Patterned Oral Somatosensory Entrainment for Shortening Time to Oral Feeding

Infant, Extremely Premature | Length of Stay | Feeding

United States
Indizen Optical Technologies, S.L.U.
Universidad Europea de Madrid

Recruiting

Evaluation of the Efficacy in Decreasing Myopia Progression of the Proposed Ophthalmic Lens Prototypes

Myopia

Spain
Centre Hospitalier Universitaire de Nīmes
Dedienne Sante S.A.S.

Terminated

Evaluation After Reconstruction of the Anterior Cruciate Ligament of the Knee Using the Bioresorbable Interference Screw (SMS): Resorbability, Per- and Post-operative Complications and Articular Functional Recovery. (BIORELICA)

Anterior Cruciate Ligament Rupture

France
Merck KGaA, Darmstadt, Germany
Merck Serono S.A.S, France

Completed

To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in France (ECOS FRA)

Growth Disorders

France
Merck KGaA, Darmstadt, Germany
Merck Serono S.A.S, France

Completed

Analysis of Two Therapeutic With Cetrotide® in Polycystic Ovarian (PCO) Women in Assisted Reproductive Technology (ART) (ATTAC-PCO)

Polycystic Ovarian Syndrome

France
CES University
Nutreva S.A.S.; Foundation Child Care - FAN

Completed

Zinc Sulphate vs. Zinc Amino Acid Chelate (ZAZO)

Diarrhea | Acute Respiratory Infection

Colombia
CES University
Nutreva S.A.S.; Foundation Child Care - FAN

Completed

Ferrous Sulfate Versus Iron Amino Acid Chelate

Iron Deficiency

Colombia
Xenova Biomedix

Unknown

Immunotoxin Therapy in Treating Children With Progressive or Recurrent Glioblastoma Multiforme or Anaplastic Astrocytoma

Brain and Central Nervous System Tumors

United States
Pega-One S.A.S.
ICON plc

Withdrawn

Imgatuzumab in Patients With Advanced Cutaneous Squamous Cell Carcinoma (I-PACE)

Cutaneous Squamous Cell Carcinoma
Merck KGaA, Darmstadt, Germany
Merck Serono S.A.S, France

Completed

Efficacy and Safety Evaluation of Recombinant Human Growth Hormone (r-hGH), Saizen®, on a Population of Children With Hypochondroplasia, Treated at Least 3 Years or Until Near Final Height, When Applicable, in Comparison With a Historic Cohort of Non-treated Children

Hypochondroplasia

France
Asofarma S.A.I. y C.
Zenith Technology Corporation Limited

Completed

Bioequivalence Study of a Test Capsule Formulation of Fingolimod With the Reference Capsule Formulation of Fingolimod

Healthy Volunteers

New Zealand
Merck KGaA, Darmstadt, Germany
Merck Serono S.A.S, France

Completed

A Multicentre Study of the Efficacy and Safety of Supplementary Treatment With Cholecalciferol in Patients With Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta-1a 44 µg 3 Times Weekly (CHOLINE)

Multiple Sclerosis

France
Centre Hospitalier Universitaire de Nīmes
Invacare Poirier S.A.S.

Completed

Comparative Measurements of Interface Pressures Between Two Pressure-ulcer Prevention Mattresses: Softform Premier and Airsoft Duo (SPA2-INVACARE)

Pressure Ulcer

France
Merck KGaA, Darmstadt, Germany
Merck Serono S.A.S, France

Completed

A Pharmaco-epidemiological Study of Short Patients Born Small for Gestational Age (SGA), Treated With Saizen® (Recombinant Somatropin) (SEPAGE)

Infant, Small for Gestational Age

France
Merck KGaA, Darmstadt, Germany
Merck Serono S.A.S, France

Terminated

EXpression PRofile Endometrium Samples Study (EXPRESS)

In Vitro Fertilization

France
Merck KGaA, Darmstadt, Germany
Merck Serono S.A.S, France

Completed

Evaluation of Emotional Disorders During Treatment by Interferon Beta in Relapsing-remitting Multiple Sclerosis Patients (SEPTIME)

Multiple Sclerosis, Relapsing, Remitting
Beijing StarMab Biomed Technology Ltd

Recruiting

Clinical Study of SM3321 With Solid Tumors

Locally Advanced or Metastatic Solid Tumors

China
Harbour BioMed (Guangzhou) Co. Ltd.

Recruiting

A Trial of HBM9378 in Healthy Chinese Subjects

Asthma

China
Harbour BioMed (Guangzhou) Co. Ltd.

Not yet recruiting

HBM4003 Combine With Toripalimab in Patients With Advanced NEN and Other Solid Tumors Study

Solid Tumors
Harbour BioMed (Guangzhou) Co. Ltd.

Recruiting

A Study to Evaluate the Efficacy and Safety of HBM9161 on Moderate to Severe Thyroid Eye Disease

Thyroid Ophthalmopathy

China
Matrix Biomed, Inc.
MedStar Georgetown

Not yet recruiting

MBM-02 (Tempol) for the Treatment of Glioblastoma Multiforme (GBM)

Glioblastoma | Glioblastoma Multiforme

United States
Harbour BioMed (Guangzhou) Co. Ltd.

Not yet recruiting

A Study to Evaluate Safety, Tolerability, PK/PD and Preliminary Efficacy of HBM4003 Combined With Anti-PD-1 Antibody

Solid Tumor
Harbour BioMed (Guangzhou) Co. Ltd.

Not yet recruiting

Study Investigating Safety,Tolerability,Pharmacokinetics and Antitumor Activities of HBM4003 Combine With Toripalimab

Solid Tumors
Harbour BioMed (Guangzhou) Co. Ltd.

Completed

A Study to Evaluate the Efficacy, Safety and PD and PK of HBM9161 in MG Patients

Myasthenia Gravis

China
Harbour BioMed (Guangzhou) Co. Ltd.

Completed

A Study Evaluating the Efficacy and Safety on Moderate to Severe Dry Eye

Dry Eye

China
Fundació Eurecat
Laboratorio Echevarne; Health Tech Bio Actives, S.L.U.

Recruiting

Effect of Methylcobalamin and Cyanocobalamin Consumption on Vitamin B12 Nutritional Status (NORMB12)

Vitamin B12 Nutritional Deficiency

Spain
iVascular S.L.U.
FCRE (Foundation for Cardiovascular Research and Education)

Recruiting

Investigating the Safety and Clinical Performance of Seven iVascular Devices for Endovascular Intervention in the Popliteal and/or Infrapopliteal Arteries (POP-BTK)

Peripheral Arterial Disease Below The Knee

Belgium
ITF Research Pharma, S.L.U.
Spanish Breast Cancer Research Group

Completed

A Clinical Trial to Assess the Safety of 0.005 % Estriol Vaginal Gel in Hormone Receptor-Positive Postmenopausal Women With Early Stage Breast Cancer in Treatment With Aromatase Inhibitor in the Adjuvant Setting (BLISSAFE)

Vaginal Atrophy

Spain, Sweden
Harbour BioMed (Guangzhou) Co. Ltd.

Recruiting

Evaluate the Efficacy and Safety of HBM9161(HL161)Subcutaneous Injection in Patients With Generalized MG Patients (MG)

Myasthenia Gravis

China
Harbour BioMed (Guangzhou) Co. Ltd.

Recruiting

A Study Evaluating HBM9036 Efficacy and Safety on Moderate to Severe Dry Eye

Dry Eye

China

3

Subscribe